Bispecific antibodies continue immuno-oncology drive

نویسندگان

چکیده

Recent deals involving bispecific antibodies illustrate the growing breadth of cancer immunotherapy applications for this platform.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

OncOlOgy – The Bispecific ApprOAch

In the days before the internet became public, the word processor was an enhanced writing instrument. Then electronic messaging came along, and the same box became a tool for creating content as well as delivering it. Could a similar shift be taking place in the field of antibody therapeutics? The modern antibody therapeutic is a monospecific compound that recognises a single antigen on an inva...

متن کامل

Bispecific antibodies.

Bispecific antibodies (bsAbs) combine specificities of two antibodies and simultaneously address different antigens or epitopes. BsAbs with 'two-target' functionality can interfere with multiple surface receptors or ligands associated, for example with cancer, proliferation or inflammatory processes. BsAbs can also place targets into close proximity, either to support protein complex formation ...

متن کامل

The immuno-oncology framework

Developers of cancer immunotherapy have struggled for decades to achieve clinical success in using the patient's immune system to treat cancer. In the absence of a defined development paradigm for immunotherapies, conventional criteria established for chemotherapy were applied to these agents. This article summarizes the recent lessons for development of agents in the immunotherapy space, descr...

متن کامل

Bispecific Antibodies Against HIV

Synergistic bispecific antibodies against HIV exhibit extraordinary potency and breadth of neutralization as promising candidates for treatment and prevention.

متن کامل

[Bispecific antibodies: what future?].

Monoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR-expressing cells. Attempts to improve the cytotoxicity of antibodies, particularly in the cancer field, have led to the design of bispecific antibodies: this can occur t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Biopharma Dealmakers

سال: 2021

ISSN: ['2730-6275', '2730-6283']

DOI: https://doi.org/10.1038/d43747-021-00096-w